MSTFA Industries is raising a $250,000 seed round at a $1.5M pre-money valuation, alongside a non-dilutive NSF SBIR Phase I application. This page states the thesis, the numbers, and the risks.
Standalone health wearables compete on hardware features and churn accordingly. MSTFA's design is different: three instruments on one engineering platform, one data plane, and cross-signal models that improve as each instrument is adopted.
The hardware moat is real — consumer wearables cannot do EEG without mastoid contact, and a standalone spirometer never sees the autonomic context that sharpens respiratory prediction. The data architecture turns that into compounding advantage while remaining fully exportable by the patient.
The raise funds three milestones: first-party prototype validation across the device portfolio, the first bench comparison against clinical reference instruments, and regulatory pre-submission groundwork.
Unit economics are modeled per program — current hardware bill of materials for Spira is approximately $146 per unit at prototype volume against a $450 target retail, with margins improving at production volume.
All three devices are pre-clinical. Models are trained on public datasets, not yet on MSTFA hardware in MSTFA cohorts. Regulatory pathways are identified but not yet entered. These are the precise risks this round is designed to retire.
What exists today: working software prototypes, completed CAD hardware design, a live FHIR data plane with fourteen endpoints, a written clinical endorsement of the Neura methodology, and a defined four-stage validation path per program.
Deck, financial model, and technical appendix — sent directly. Select “Investment interest” on the contact form.